Q-omics provides the consensus-scored MIR4659A profile across patient tissues and cancer cell-line models. MIR4659A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR4659A is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, MIR4659A RNA expression shows 10,215 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UVM, STAD, and LAML as cancer lineages where MIR4659A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4659A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4659A survival associations across molecular data types. MIR4659A RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4659A RNA expression–survival associations across cancer types. High MIR4659A expression shows unfavorable associations in UVM, MESO, THCA, DLBC and LUSC, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR4659A RNA expression.
This table summarizes MIR4659A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4659A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4659A shows lower tumor expression in COAD and higher tumor expression in STAD, LUSC, LUAD, PRAD and KIRC. The STAD box plot shows higher MIR4659A RNA expression in tumor versus normal tissue (log2 FC = +0.544, t-test p < 0.001).
This table shows molecular features associated with MIR4659A in patient tissues and cancer cell lines. In patient samples, MIR4659A shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
